Type 2 Diabetes Mellitus Completed Phase 1 Trials for Metformin (DB00331)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02749032Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) SecretionTreatment
NCT02813863The Drug-drug Interaction of SP2086 and MetforminTreatment
NCT00865033A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting ConditionsTreatment
NCT00961480A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)Treatment
NCT00961857A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)Treatment
NCT00971659Adjunctive Therapy of Exenatide or Sitagliptin to Insulin Glargine in Type 2 DiabetesTreatment
NCT00975052A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)Treatment
NCT01093794Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)Treatment
NCT01089179Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions
NCT01089166Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition
NCT01089205Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.
NCT01089192Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.
NCT01726764Interaction Between St John's Wort and Metformin?
NCT01747083Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)
NCT01869621Study of Metformin Pharmacogenetics in TwinsBasic Science
NCT02354027The Drug-drug Interaction of SHR3824 and MetforminTreatment
NCT00673465Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)Treatment
NCT01557504A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)Treatment
NCT02411825Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) PatientsBasic Science
NCT01154348Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes MellitusTreatment
NCT03138356Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy SubjectsTreatment
NCT01302145Drug to Drug Interaction Study With ASP1941 and MetforminBasic Science
NCT00376038Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 DiabetesTreatment
NCT00519480A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of MetforminTreatment
NCT00830076A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)Treatment
NCT00897390Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
NCT00899470Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
NCT00929201Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)Treatment
NCT01068730Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
NCT01068717Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
NCT01068743Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
NCT01292993A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy SubjectsTreatment
NCT01365091Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil
NCT01535677To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered SeparatelyBasic Science
NCT01546597Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
NCT01546558Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
NCT01681693Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African AmericansDiagnostic
NCT01941199Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male SubjectsTreatment
NCT01956305Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose StudyTreatment
NCT02167061A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male VolunteersTreatment
NCT02375139A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male VolunteersTreatment
NCT02597400Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DMTreatment
NCT01002807Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
NCT01755494A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-AdministrationBasic Science
NCT00961909A Study of RO5095932 in Patients With Type 2 Diabetes MellitusTreatment
NCT03686722Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of MetforminOther
NCT02722239An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed ConditionsTreatment
NCT03061981A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male SubjectsTreatment
NCT03310749An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican VolunteersTreatment
NCT01383356Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin TabletBasic Science
NCT01332071Avandamet Bioequivalence Study Brazil - Fed Administration
NCT01489644Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy VolunteersTreatment
NCT01490658Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy VolunteersTreatment
NCT02022254Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy SubjectsTreatment
NCT01211197Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on BioavailabilityTreatment
NCT01780051A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two ComponentsTreatment
NCT00882882To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting ConditionsTreatment
NCT02685774A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male VolunteersTreatment
NCT01728740Bioequivalence Study for Acarbose / Metformin FDC
NCT02565368A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male VolunteersTreatment
NCT02627027A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male VolunteersTreatment
NCT02648854Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male VolunteersTreatment